- Home
- MITT vs DSGN Comparison
MITT vs DSGN Comparison
Compare MITT & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MITT
- DSGN
- Stock Information
- Founded
- MITT 2011
- DSGN 2017
- Country
- MITT United States
- DSGN United States
- Employees
- MITT N/A
- DSGN N/A
- Industry
- MITT Real Estate Investment Trusts
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- MITT Real Estate
- DSGN Health Care
- Exchange
- MITT Nasdaq
- DSGN Nasdaq
- Market Cap
- MITT 230.0M
- DSGN 208.9M
- IPO Year
- MITT 2011
- DSGN 2021
- Fundamental
- Price
- MITT $7.76
- DSGN $5.95
- Analyst Decision
- MITT Strong Buy
- DSGN
- Analyst Count
- MITT 5
- DSGN 0
- Target Price
- MITT $8.50
- DSGN N/A
- AVG Volume (30 Days)
- MITT 146.3K
- DSGN 162.2K
- Earning Date
- MITT 11-04-2025
- DSGN 11-06-2025
- Dividend Yield
- MITT 10.73%
- DSGN N/A
- EPS Growth
- MITT N/A
- DSGN N/A
- EPS
- MITT 0.86
- DSGN N/A
- Revenue
- MITT $83,509,000.00
- DSGN N/A
- Revenue This Year
- MITT N/A
- DSGN N/A
- Revenue Next Year
- MITT $13.95
- DSGN N/A
- P/E Ratio
- MITT $9.12
- DSGN N/A
- Revenue Growth
- MITT 25.02
- DSGN N/A
- 52 Week Low
- MITT $5.63
- DSGN $2.60
- 52 Week High
- MITT $7.95
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- MITT 55.98
- DSGN 56.54
- Support Level
- MITT $7.62
- DSGN $5.80
- Resistance Level
- MITT $7.88
- DSGN $6.65
- Average True Range (ATR)
- MITT 0.13
- DSGN 0.48
- MACD
- MITT 0.01
- DSGN -0.06
- Stochastic Oscillator
- MITT 62.06
- DSGN 55.09
About MITT AG Mortgage Investment Trust Inc.
AG Mortgage Investment Trust Inc is a real estate investment trust (REIT). It focuses on investing in a diversified risk-adjusted portfolio of residential mortgage-related assets in the U.S. mortgage market. Its objective is to provide attractive risk-adjusted returns to its stockholders over the long term through dividends and capital appreciation. It also focuses on investing in residential mortgage-backed securities (RMBS) issued or guaranteed by a government-sponsored enterprise.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.